Literature DB >> 11888529

Haptoglobin phenotype and coronary artery collaterals in diabetic patients.

Irit Hochberg1, Ariel Roguin, Eugenia Nikolsky, Patil V Chanderashekhar, Silviu Cohen, Andrew P Levy.   

Abstract

Cross-cultural epidemiological studies of incident cardiovascular disease in the diabetic patient have demonstrated marked differences in susceptibility that may be due to a genetic factor. The coronary artery collateral circulation is the chief determinant of the size of a myocardial infarction and is highly variable between patients. We recently demonstrated that a functional allelic polymorphism in the haptoglobin gene is correlated with a number of diabetic vascular complications. We thus set out to test the hypothesis that haptoglobin phenotype is associated with collateral formation in the setting of diabetes. We correlated the Hp phenotype (1-1, 2-1 or 2-2) as determined by polyacrylamide electrophoresis with the presence or absence of coronary collaterals by angiography in 82 consecutive diabetic patients and 138 consecutive non-diabetic patients undergoing catheterization. We found that diabetic patients with the Hp phenotype 2-1 were more likely to have collaterals than diabetic patients with the Hp phenotype 2-2 (P=0.007). There was no correlation between Hp phenotypes and the presence of collaterals in non-diabetic patients. Hp phenotype thus appears to be associated with the development of the coronary collateral circulation in diabetic patients with coronary artery disease. Haptoglobin 2-2 may predispose to less compensation for coronary artery stenosis in diabetic patients, and thereby portend a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888529     DOI: 10.1016/s0021-9150(01)00657-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

1.  Type 2 diabetes mellitus and its complications: from the molecular biology to the clinical practice.

Authors:  Maciej T Malecki
Journal:  Rev Diabet Stud       Date:  2004-05-10

2.  The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype.

Authors:  Leah E Cahill; Majken K Jensen; Stephanie E Chiuve; Hadar Shalom; Jennifer K Pai; Alan J Flint; Kenneth J Mukamal; Kathryn M Rexrode; Andrew P Levy; Eric B Rimm
Journal:  J Am Coll Cardiol       Date:  2015-10-20       Impact factor: 24.094

Review 3.  Coronary collateral growth--back to the future.

Authors:  William M Chilian; Marc S Penn; Yuh Fen Pung; Feng Dong; Maritza Mayorga; Vahagn Ohanyan; Suzanna Logan; Liya Yin
Journal:  J Mol Cell Cardiol       Date:  2011-12-19       Impact factor: 5.000

4.  Haptoglobin genotype modulates the relationships of glycaemic control with cognitive function in elderly individuals with type 2 diabetes.

Authors:  Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Andrew Levy; Derek Leroith; Michal S Beeri
Journal:  Diabetologia       Date:  2015-01-28       Impact factor: 10.122

Review 5.  Applications of microfluidics and microchip electrophoresis for potential clinical biomarker analysis.

Authors:  Jayson V Pagaduan; Vishal Sahore; Adam T Woolley
Journal:  Anal Bioanal Chem       Date:  2015-04-09       Impact factor: 4.142

6.  Haptoglobin phenotype, angiogenic factors, and preeclampsia risk.

Authors:  Tracey L Weissgerber; James M Roberts; Arun Jeyabalan; Robert W Powers; Minjae Lee; Saul A Datwyler; Robin E Gandley
Journal:  Am J Obstet Gynecol       Date:  2012-01-13       Impact factor: 8.661

7.  Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).

Authors:  Trevor J Orchard; Jye-Yu C Backlund; Tina Costacou; Patricia Cleary; Maria Lopes-Virella; Andrew P Levy; John M Lachin
Journal:  J Diabetes Complications       Date:  2016-07-25       Impact factor: 2.852

8.  An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype.

Authors:  Nina S Levy; Moshe Vardi; Shany Blum; Rachel Miller-Lotan; Yefim Afinbinder; Patricia A Cleary; Andrew D Paterson; Bhupinder Bharaj; Janet K Snell-Bergeon; Marian J Rewers; Orit Lache; Andrew P Levy
Journal:  Clin Chem Lab Med       Date:  2013-08       Impact factor: 3.694

9.  Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin.

Authors:  Leah E Cahill; Andrew P Levy; Stephanie E Chiuve; Majken K Jensen; Hong Wang; Nawar M Shara; Shany Blum; Barbara V Howard; Jennifer K Pai; Kenneth J Mukamal; Kathryn M Rexrode; Eric B Rimm
Journal:  J Am Coll Cardiol       Date:  2013-01-09       Impact factor: 24.094

10.  Haptoglobin: A major susceptibility gene for diabetic vascular complications.

Authors:  Tal Szafranek; Stuart Marsh; Andrew P Levy
Journal:  Exp Clin Cardiol       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.